Distinct autoantibody profiles across checkpoint inhibitor types and toxicities-Reference-Cited by-同舟云学术

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

Published:2024-05-09 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Mu-Mosley Hong¹,von Itzstein Mitchell S.¹²,Fattah Farjana¹,Liu Jialiang³,Zhu Chengsong⁴,Xie Yang¹³⁵,Wakeland Edward K.⁴,Park Jason Y.⁶,Kahl Brad S.⁷,Diefenbach Catherine S.⁸,Gerber David E.¹²⁵^ORCID

Affiliation:

1. Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA

2. Division of Hematology-Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA

3. Quantitative Biomedical Research Center, UT Southwestern Medical Center, Dallas, TX, USA

4. Department of Immunology, UT Southwestern Medical Center, Dallas, TX, USA

5. Peter O’Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA

6. Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA

7. School of Medicine, Washington University,Louis, MO, USA

8. Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA

Funder

National Cancer Institute

American Cancer Society

Physician-Scientist Institutional Award from the Burroughs Wellcome Fund

the Harold C. Simmons Comprehensive Cancer Center Data Sciences Shared Resource

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2351255

Reference31 articles.

1. Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

2. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

3. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

4. Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

5. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance;Cell Communication and Signaling;2024-06-19